Evidence map›Paper›PMID 30564155›Full record

ReviewFrontiers in psychiatry2018

Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder.

Hannah Zuckerman, Zihang Pan, Caroline Park, Elisa Brietzke, Natalie Musial, Aisha S Shariq, Michelle Iacobucci, Samantha J Yim, Leanna M W Lui, Carola Rong and 1 more

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04589637 (Factors Influencing the Deterioration From Cognitive Decline of Normal Aging to Dementia Among Nursing Home Residents), which is not on this map. Cited by 103 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 5 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04589637 completednot on this map

Factors Influencing the Deterioration From Cognitive Decline of Normal Aging to Dementia Among Nursing Home Residents

TypeobservationalSponsorJordan University of Science and TechnologyRan2018 to 2019Enrolled182ConditionsDementia
3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 5 syntheses or guidelines pooled it, 252 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Hannah ZuckermanMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Zihang PanMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Caroline ParkMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Elisa BrietzkeMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Natalie MusialMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Aisha S ShariqMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Michelle IacobucciMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Samantha J YimMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Leanna M W LuiMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Carola RongMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Roger S McIntyreMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
University Health Network · CAUniversidade Federal de São Paulo · BRUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major Depressive Disorder (MDD) is a prevalent, chronic, disabling, and multidimensional mental disorder. Cognitive dysfunction represents a core diagnostic and symptomatic criterion of MDD, and is a principal determinant of functional non-recovery. Cognitive impairment has been observed to persist despite remission of mood symptoms, suggesting dissociability of mood and cognitive symptoms in MDD. Recurrent impairments in several domains including, but not limited to, executive function, learning and memory, processing speed, and attention and concentration, are associated with poor psychosocial and occupational outcomes. Attempts to restore premorbid functioning in individuals with MDD requires regular screenings and assessment of objective and subjective measures of cognition by clinicians. Easily accessible and cost-effective tools such as the THINC-integrated tool (THINC-it) are suitable for use in a busy clinical environment and appear to be promising for routine usage in clinical settings. However, antidepressant treatments targeting specific cognitive domains in MDD have been insufficiently studied. While select antidepressants, e.g., vortioxetine, have been demonstrated to have direct and independent pro-cognitive effects in adults with MDD, research on additional agents remains nascent. A comprehensive clinical approach to cognitive impairments in MDD is required. The current narrative review aims to delineate the importance and relevance of cognitive dysfunction as a symptomatic target for prevention and treatment in the phenomenology of MDD.

Indexed as

cognitioncognitive dysfunctionfunctionalitymajor depressive disordertreatment

Identifiers

PMID30564155
PMCPMC6288549
OpenAlexW2902778000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.